Novel Agents Show Promise Against Acquired Endocrine Resistance in ER plus Advanced Breast Cancer

被引：3

作者：

不详

机构：

来源：

ONCOLOGIST | 2021年 / 26卷

关键词：

D O I：

10.1002/onco.13874

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S15 / S16

页数：2

共 4 条

[1] A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer. [J].

Li, Huiping ;

Jiang, Hanfang ;

Yin, Yongmei ;

Tong, Zhongsheng ;

Ouyang, Quchang ;

Shen, Kunwei ;

Yuan, Zhongyu ;

Geng, Cuizhi ;

Ran, Ran ;

Zhang, Ruyan ;

Liu, Ya-Xin ;

Zhang, Jiayang ;

Li, Wei ;

Qu, Qing ;

Zhou, Qiaoxia ;

Dong, Xunwei ;

Meng, Luping ;

Zhu, Xiaoyan ;

Yi, Zhen ;

Tong, Youzhi .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[2] Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR plus /estrogen receptor (ER) plus breast cancer in an international phase 2 clinical study. [J].

Palmieri, Carlo ;

Linden, Hannah M. ;

Birrell, Stephen ;

Lim, Elgene ;

Schwartzberg, Lee S. ;

Rugo, Hope S. ;

Cobb, Patrick Wayne ;

Jain, Kirti ;

Vogel, Charles L. ;

O'Shaughnessy, Joyce ;

Johnston, Stephen R. D. ;

Getzenberg, Robert H. ;

Barnette, K. Gary ;

Steiner, Mitchell S. ;

Brufsky, Adam ;

Overmoyer, Beth .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[3]

Pluard TJ., 2021, 2021 AM SOC CLIN ONC, DOI DOI 10.1200/JCO.2021.39.15_SUPPL.1018

[4]

Sohn, 2021, 2021 AM SOC CLIN ONC, DOI DOI 10.1200/JCO.2021.39.15_SUPPL.1017

← 1 →